

DNB CARDIOLOGY PREVIOUS YEARS QUESTIONS PAPERS

PAPER II

1. BRAIN NATRIURETIC PEPTIDE IN HEART FAILURE
2. ELECTRICAL DEVICE THERAPY IN HEART FAILURE
3. NON ST ELEVATION ACS THE RATIONALE FOR CONSERVATIVE AND INVASIVE STRATEGIES.
4. ST ELEVATION AMI: FACILITATED REPERFUSION
5. DIURETICS IN HYPERTENSION CRITICIZE JNC 7
6. LOWER THE BETTER- WHAT SHOULD BE THE LOWER LDL -C IN SECONDARY PREVENTION.
7. SUDDEN CARDIAC DEATH DISCUSS THE PRIMARY ELECTRICAL ABNORMALITIES
8. DRUG ELUSTING STENTS AND SUBACUTE STENT THROMBOSIS
9. IHD IN YOUNG – A TROPICAL DISEASE
10. NEWER ANTI ANGINAL DRUGS
11. ASSESSMENT OF MYOCARDIAL VIABILITY
12. RISK STRATIFICATION IN ACS
13. NESIRITIDE
14. HEMODYNAMICS OF TOTAL ANOMALOUS PULMONARY VENOUS CONNECTION
15. TROPONIN
16. PRIMARY ANGIOPLASTY VS THROMBOLYSIS IN ACUTE MI
17. DRUG THERAPY FOR PULMONARY HYPERTENSION
18. RATE VS RHYTHM CONTROL IN AF

DOWNLOADED FROM WWW.DNBDOCTORS.COM

19 MANAGEMENT OF PROSTHATIC VALVE THROMBOSIS

20 HEMODYNAMICS AND ANGIOGRAPHIC DIFFERENCE BETWEEN
CONSTRICTIVE PERICARDITIS AND RESTRICTIVE CARDIOMYOPATHY

21 DISCUSS NEWER AND EVOKING RISK FACTORS AND THEIR ROLE IN
CORONARY ARTERY DISEASE

22 MECHANISM OF RESTENOSIS FOLLOWING PTCA

23 FASCICULAR TACHYCARDIA

24 MIDCABS

25 ASSESMENT OF MYOCARDIAL PERFUSION

26 MANAGEMENT OF DILATED CARDIOMYOPATHY

27 DISCUSS THE CURRENT STATUS OF PRIMARY ANGIOPLASTY

28 FONTAN SURGERY.

29 STRESS ECHO CARDIOGRAPHY

30 INFECTIONS IN THE ETIOLOGY OF CORONARY ARTERY DISEASE

31 CURRENT THERAPIES FOR THE TREATMENT OF PULMONARY
THROMBOEMBOLISM

32 DISCUSS REGRESSION TRIALS. WHAT ARE THE CURRENT
RECOMMENDATIONS OF PRIMARY PREVENTION OF ISCHEMIC HEART
DISEASE.

33 DRUG COATED STENTS

34 MANAGEMENT OF NSVT

35 MANAGEMENT OF TOF

36 Biv PACING

37 CRT

DOWNLOADED FROM WWW.DNBDOCTORS.COM

- 38 DISCUSS PHYSIOLOGICAL EVALUATION OF PATIENTS WITH WPW SYNDROME
- 39 MANAGEMENT OF CARDIAC ARRHYTHMIAS IN PREGNANCY
- 40 DIAGNOSIS, HEMODYNAMICS AND PHARMACOLOGICAL MANAGEMENT OF RV INFARCTION
- 41 TIMING OF SURGERY IN ASYMPTOMATIC AORTIC VALVE DISEASE
- 42 BETABLOCKERS IN HEART FAILURE
- 43 THERAPEUTIC ANGIOGENESIS
- 45 DISCUSS COMPREHENSIVE STRATEGY OF SECONDARY PREVENTION AFTER ACUTE MI
- 46 LAD OSTIAL LESION
- 47 ROLE OF ECHO IN HEART FAILURE
- 48 HYPERHOMOCYSTEINEMIA
- 49 CURRENT STATUS OF DIRECT MYOCARDIAL REVASCULARIZATION
- 50 ENDOTHELIAL DYSFUNCTION
- 51 DISCUSS THE CURRENT STATUS OF NONSURGICAL CLOSURE OF DIFFERENT CARDIOVASCULAR SHUNTS
- 52 CLINICAL PRESENTATION AND MANAGEMENT OF HYPERTENSION IN PREGNANCY
- 53 PROTOCOLS AND CLINICAL APPLICATION OF THALIUM SCINTIGRAPHY
- 54 LAB DIAGNOSIS AND TREATMENT OF CHRONIC CONSTRICTIVE PERICARDITIS
- 55 DIAGNOSIS OF DISSECTING ANEURYSM OF AORTA
- 56 ARRHYTHMOGENIC RIGHT VENTRICULAR DYSPLASIA (ARVD)

57 DISCUSS THE PATHOPHYSIOLOGY OF ATHEROSCLEROSIS WITH SPECIAL REFERENCE TO THE VULNERABLE PLAQUE

58 COLLATERAL CORONARY CIRCULATION

59 TREATMENT OF CULTURE NEGATIVE ENDOCARDITIS

60 TREATMENT OF HOCM

61 ROLE OF INSULIN SENSITIZERS

62 ATRIAL MIXOMA

63 DISCUSS PATHOGENESIS AND MANAGEMENT OF PRIMARY PULMONARY HYPERTENSION

64 ROLE OF BRACHYTHERAPY IN PREVENTING “RE-STENOSIS”

65 MECHANISM OF AF AND ACTIONS OF DRUGS USED IN ITS MANAGEMENT

66 STRATEGIES FOR PREVENTION OF CAD

67 HYPERTENSION IN PREGNANCY

68 ROLE OF GP IIb / III a ANTAGONIST

69 DESCRIBE IN DETAILS THE PATHOGENESIS AND MANAGEMENT OF HOCM

70 ROLE OF STATINS IN MANAGEMENT OF DYSLIPIDEMIA

71 LONG QT SYNDROME

72 HYPERTENSION IN ELDERLY

73 PATHOPHYSIOLOGY OF MICROVASCULAR ANGINA

74 RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR

75 DIAGNOSIS AND MANAGEMENT OF HYBERNATING MYOCARDIUM

DOWNLOADED FROM WWW.DNBDOCTORS.COM

- 76 ANGIOTENSIN RECEPTOR BLOCKERS
- 77 DUAL ATRIAL PACING ROLE IN ATRIAL FIBRILLATION
- 78 MANAGEMENT OF ASYMPTOMATIC CAROTID ARTERY STENOSIS
- 78 DEVICE / COIL CLOSURE OF PDA
- 79 FONTAN OPERATION INDICATIONS AND FOLLOW UP RESULTS
- 80 FAILING FONTAN
- 81 ASPIRIN IN HEART FAILURE
82. MECHANISM OF SUDDEN CARDIAC DEATH AND ITS PREVENTION
- 83 ROLE OF PACE MAKER IN HOCM
- 84 SYNDROME X
- 85 PROSTHATIC VALVE ENDOCARDITIS
- 86 VACCINE FOR RHEUMATIC FEVER
- 87 DISCUSS RISK STRATIFICATION AFTER MI
- 88 PHYSIOLOGICAL PACING
- 89 DISCUSS RECENT TRENDS IN MANagements OF HOCM
- 90 MANAGEMENT OF RECURRENT PULMONARY THROMBOEMBOLISM
- 91 ASYMPTOMATIC AR WHEN TO OPERATE
- 92 DIAGNOSIS AND MANAGEMENT OF REJECTION AFTER CARDIAC TRANSPLANT
- 93 MYOCARDIAL STUNNING PATHOGENESIS AND CLINICAL SIGNIFICANCE
- 94 RADIOFREQUENCY ENERGY AND ITS APPLICATION IN ARRHYTHMIAS
- 95 CORONARY RISK FACTORS IN INDIANS

96 ANTI ARRHYTHMIC DRUGS VS ICD IN THE MANAGEMENT OF VT

97 ADENOSIN

98 ACE INHIBITORS IN LEFT VENTRICULAR DYSFUNCTION- USEFULNESS AND PRECISE MECHANISM

99 MANAGEMENT OF COMPLEX VENTRICULAR ARRHYTHMIAS IN POST MI PHASE

100 RATE RESPONSIVE SENSORS

101 L-CARNITINE

102 RHEUMATIC FEVER PROPHYLAXIS CURRENT RECOMMENDATIONS

103 DISCUSS PATHOPHYSIOLOGY OF UNSTABLE PLAQUE AND ITS RELEVANCE IN ACS

104 CURRENT INDICATIONS OF PPI IN CONGENITAL AV BLOCKS

105 PRESENT INDICATIONS FOR LASER CORONARY ANGIOPLASTY

106 PREVALENCE OF METABOLIC SYNDROME TO CAD IN SOUTH EASTERN ASIAN

107 LONG TERM MANAGEMENT OF VALVULAR REGURGITANT LESIONS BY USING ACE INHIBITORS – RATIONALES AND RESULTS

108 CURRENT GUIDELINES FOR CATHETER ABLATION FOR CARDIAC ARRHYTHMIA MANAGEMENT

109 DISCUSS THE CONCEPT OF MYOCARDIAL PRECONDITIONING AND ITS RELEVANCE TO CLINICAL CARDIAC PRACTICE

110 VALUE AND INDICATIONS OF IABP IN CCU
MONOMORPHIC VT ITS CLINICAL FEATURES ECG FINDINGS AND PRESENT DAY MANAGEMENT

DOWNLOADED FROM WWW.DNBDOCTORS.COM

111. STATINS AND THEIR ROLE IN CAUSING PLAQUE REGRESSION IN PERSON WITH KNOWN CAD
- 112 CURRENT ROLE OF DIAGNOSTIC CATHETERIZATION IN PATIENTS WITH VALVULAR HEART DISEASE
- 113 DYNAMIC CARDIOMYOPLASTY FOR LATE STAGE CARDIAC FAILURE
- 114 DISCUSS MANAGEMENT OF RESISTANT VENTRICULAR ARRHYTHMIAS
- 115 DISCUSS MITRAL VALVE SURGERIES
- 116 PACEMAKER SYNDROME
- 117 AMIODARONE
- 118 Y- DESCENT IN NECK VEIN
- 119 MITRAL VALVE PROLAPSE
- 120 DIRECT ATHERECTOMY
- 121 NON-SURGICAL CLOSURE OF ASD
- 122 DISCUSS ELECTROPHYSIOLOGICAL EVALUATION OF SINUS NODE FUNCTIONS
- 123 DISCUSS CLINICAL PATHOLOGICAL HEMODYNAMIC PROFILE OF EMF
- 124 ESTABLISHMENT OF CATH LAB
- 125 ROLE OF THROMBOLYTIC THERAPY IN ACUTE MI
- 126 SALVAGE ANGIOPLASTY
- 127 VIABLE ISCHEMIC MYOCARDIUM
128. DISCUSS PROGRESS IN EVALUATION AND MANAGEMENT OF WPW SYNDROME
- 129 ANGIOSCOPY

- 130 MARKERS OF MYOCARDIAL VIABILITY
- 131 DISCUSS PROSTHATIC VALVE MALFUNCTION
- 132 CARDIAC TRANSPLANTATION
- 133 VENTRICULAR REMODLING
- 134 SUBMITRAL ANURYSM
- 135 ANTIBODIES IN THE TREATMENT OF CARDIOVASCULAR DISEASE
- 136 NONCOMPACTION OF LV
- 137 INTERVENTIONS DURING CARDIOGENIC SHOCK
- 138 LOW PRESSURE TR
- 139 REGURGITANT LESIONS MEDICAL MANAGEMENT
- 140 LIFE STYL MODIFICATIONS
- 141 SVT DIAGNOSIS AND MANAGEMENT
- 142 ANTIPLATLETE DRUGS
- 143 DISCUSS THE METHODS OF ASCESSMENT OF REPERFUSION AFTER THROMBOLYTIC THERAPY
- 144 DISCUSS THE RELATIVE MERITS OF THE METHODS OF ASCESSING LEFT TO RIGHT SHUNTS IN CARDIOLOGY
- 145 DISCUSS THE CARDIOVASCULAR CHANGES AND MANAGEMENT OF MS DURING PREGNANCY
- 146 DISCUSS THE RELATIVE MERITS OF PCI VS CABG IN MULTIVESSEL CAD
- 147 DESCRIBE THE NEWER TRENDS IN THE MANAGEMENT OF DCM
- 148 DISCUSS THE CADIAC INVOLVEMENT IN ENDOCRINE DISORDERS

- 149 PREVENTIVE MEASURES OF CADIN INDIAN POPULATION
- 150 THE PRINCIPLE AND UTILITY OF IMPLANTABLE ANTI TACHYCARDIA DEVICES
- 151 THE ACTION DOSES AND PRESENT STATUS OF ASPIRIN IN CLINICAL CARDIOLOGY
- 152 THE PATHOGENESIS, DIAGNOSIS AND MANAGEMENT OF AORTIC DISSECTTION
- 153 THE PROARRTHYMIAS, CAUSES, RECOGNISITION AND MANAGEMNENT
- 154 DISCUSS THE MANAGEMENT OF CARDIOGENIC SHOCK
- 155 THE PREVENTIVE MEASURES FOR RHEUMATIC FEVER
- 156 NEW DEVICES IN CORONARY INTERVENTION
- 157 CURRENT STATUS OF AORTIC VALVOPLASTY
- 158 ROLE OF AMIODARONE AFTER MI
- 159 DISCUSS THE ROLE OF ACE INHIBITORS AFTER ACUTE MI
- 160 MANAGEMENT OF CARDIAC TEMPONADE
- 161 DIASTOLIC HEART FAILURE AND THERAPUTIC IMPLICATION
- 162 THERAPUTIC STATIGIES FOR FAMILIAL HYPERCHOLESTEROLEMIA